Linked Life Data

1706389

Source:http://linkedlifedata.com/resource/pubmed/id/1706389

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
1991-4-22
pubmed:abstractText
We have developed a mAb anti-6C2, by immunizing mice with T cell line derived from the Callithrix jacchus (common marmoset). Anti-6C2 is reactive with approximately 50% of unfractionated T cells, 50% of CD4+ cells, and 40% of CD8+ cells. Regarding CD4+ cells, anti-6C2-reactive cells substantially overlap with the CD29+CD45RO+ Th cell population. Moreover, anti-6C2 can divide these T cells into 6C2+ and 6C2- subpopulations. The CD4+CD45RO+6C2+ cells maximally respond to soluble Ag such as tetanus toxoid and provide strong helper function for PWM-driven B cell IgG synthesis. Most interestingly, anti-6C2 was also reactive against activated B cells but not resting B cells; furthermore, this epitope was inducible through activation of resting B cells or B cell line. Biochemical characterization showed that anti-6C2 precipitated two glycoproteins with the relative molecular weights of 180,000 and 95,000 from 125I-surface labeled cell lysate. Sequential immunoprecipitation studies demonstrated that these two glycoproteins were the lymphocyte function-associated antigen (LFA-1) Ag complex (CD11a/18). Significantly, although this antibody did not inhibit cytotoxic killer T cell responses and Ag-induced T cell proliferation as did conventional anti-LFA-1, it did inhibit PWM-driven B cell IgG synthesis. Because 6C2 expression was induced after B cell activation, the above results strongly suggest that the 6C2 molecule may play a role in the interaction of CD4 helper cells and activated B lymphocytes.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
146
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2176-84
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:1706389-Antibodies, Monoclonal, pubmed-meshheading:1706389-Antigens, CD, pubmed-meshheading:1706389-Antigens, CD29, pubmed-meshheading:1706389-Antigens, CD45, pubmed-meshheading:1706389-Antigens, CD8, pubmed-meshheading:1706389-Antigens, Differentiation, pubmed-meshheading:1706389-Antigens, Differentiation, T-Lymphocyte, pubmed-meshheading:1706389-B-Lymphocytes, pubmed-meshheading:1706389-CD4-Positive T-Lymphocytes, pubmed-meshheading:1706389-Histocompatibility Antigens, pubmed-meshheading:1706389-Humans, pubmed-meshheading:1706389-Immunoglobulin G, pubmed-meshheading:1706389-Lymphocyte Activation, pubmed-meshheading:1706389-Lymphocyte Cooperation, pubmed-meshheading:1706389-Lymphocyte Function-Associated Antigen-1, pubmed-meshheading:1706389-Molecular Weight, pubmed-meshheading:1706389-T-Lymphocyte Subsets, pubmed-meshheading:1706389-T-Lymphocytes, Helper-Inducer
pubmed:year
1991
pubmed:articleTitle
Development of a monoclonal antibody, anti-6C2, which is involved in the interaction of CD4 T helper cells and activated B cells.
pubmed:affiliation
Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA 02115.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.